	Name	Trade name	Type	Source	Target	Use
5	Abituzumab[3]		mab	humanized	CD51	cancer
9	Adecatumumab[6]		mab	human	EpCAM	prostate and breast cancer
13	Afutuzumab[9]		mab	humanized	CD20	lymphoma
14	Alacizumab pegol[10]		F(ab')2	humanized	VEGFR2	cancer
19	Amatuximab[14]		mab	chimeric	mesothelin	cancer
21	Anetumab ravtansine[3]		mab	human	MSLN	cancer
24	Apolizumab[17]		mab	humanized	HLA-DR ?	hematological cancers
26	Ascrinvacumab[18]		mab	human	activin receptor-like kinase 1	cancer
28	Atezolizumab[20]		mab	humanized	CD274	cancer
32	Avelumab[8]		mab	human	CD274	?
35	Bavituximab[2]		mab	chimeric	phosphatidylserine	cancer, viral infections
42	Bevacizumab[12]	Avastin	mab	humanized	VEGF-A	metastatic cancer, retinopathy of prematurity
54	Brentuximab vedotin[33]		mab	chimeric	CD30 (TNFRSF8)	hematologic cancers
58	Brontictuzumab[23]		mab	humanized	Notch 1	cancer
62	Cantuzumab mertansine		mab	humanized	mucin CanAg	colorectal cancer etc.
63	Cantuzumab ravtansine[30]		mab	humanized	MUC1	cancers
68	Catumaxomab[22]	Removab	3funct	rat/mouse hybrid	EpCAM, CD3	ovarian cancer, malignant ascites, gastric cancer
69	cBR96-doxorubicin immunoconjugate		mab	humanized	Lewis-Y antigen	cancer
73	Cetuximab	Erbitux	mab	chimeric	EGFR	metastatic colorectal cancer and head and neck cancer
74	Citatuzumab bogatox[9]		Fab	humanized	EpCAM	ovarian cancer and other solid tumors
75	Cixutumumab		mab	human	IGF-1 receptor (CD221)	solid tumors
78	Clivatuzumab tetraxetan[40]	hPAM4-Cide	mab	humanized	MUC1	pancreatic cancer
79	Codrituzumab[3]		mab	humanized	glypican 3	cancer
80	Coltuximab ravtansine[3]		mab	chimeric	CD19	cancer
81	Conatumumab[9]		mab	human	TRAIL-R2	cancer
86	Dacetuzumab[10]		mab	humanized	CD40	hematologic cancers
88	Dalotuzumab[42]		mab	humanized	IGF-1 receptor (CD221)	cancer etc.
90	Daratumumab[43]		mab	human	CD38 (cyclic ADP ribose hydrolase)	cancer
92	Demcizumab[44]		mab	humanized	DLL4	cancer
93	Denintuzumab mafodotin[23]		mab	humanized	CD19	cancer
94	Denosumab[45]	Prolia	mab	human	RANKL	osteoporosis, bone metastases etc.
95	Depatuxizumab mafodotin[32]		mab	chimeric/humanized	EGFR	cancer
96	Derlotuximab biotin[46]		mab	chimeric	histone complex	recurrent glioblastoma multiforme
98	Dinutuximab[47]		mab	chimeric	GD2 ganglioside	neuroblastoma
102	Drozitumab[50]		mab	human	DR5	cancer etc.
103	Duligotumab[51]		mab	human	ERBB3 (HER3)	testicular cancer
105	Durvalumab[53]		mab	human	CD274	cancer
106	Dusigitumab[54]		mab	human	ILGF2	cancer
107	Ecromeximab[17]		mab	chimeric	GD3 ganglioside	malignant melanoma
114	Elgemtumab[20]		mab	human	ERBB3 (HER3)	cancer
115	Elotuzumab		mab	humanized	SLAMF7	multiple myeloma
117	Emactuzumab[23]		mab	humanized	CSF1R	cancer
118	Emibetuzumab[57]		mab	humanized	HHGFR	cancer
120	Enavatuzumab[58]		mab	humanized	TWEAK receptor	cancer etc.
121	Enfortumab vedotin[59]		mab	human	AGS-22M6	cancer expressing Nectin-4
123	Enoblituzumab[61]		mab	humanized	CD276	cancer
126	Ensituximab[63]		mab	chimeric	5AC	cancer
128	Epratuzumab		mab	humanized	CD22	cancer, SLE
131	Ertumaxomab[22]	Rexomun	3funct	rat/mouse hybrid	HER2/neu, CD3	breast cancer etc.
132	Etaracizumab	Abegrin	mab	humanized	integrin αvβ3	melanoma, prostate cancer, ovarian cancer etc.
139	Farletuzumab		mab	humanized	folate receptor 1	ovarian cancer
141	FBTA05[71][72]	Lymphomun	3funct	rat/mouse hybrid	CD20	chronic lymphocytic leukaemia
145	Ficlatuzumab[76]		mab	humanized	HGF	cancer etc.
146	Figitumumab		mab	human	IGF-1 receptor (CD221)	adrenocortical carcinoma, non-small cell lung carcinoma etc.
148	Flanvotumab[77]		mab	human	TYRP1(glycoprotein 75)	melanoma
153	Fresolimumab[80]		mab	human	TGF-β	idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
155	Futuximab[51]		mab	chimeric	EGFR	cancer
157	Galiximab		mab	chimeric	CD80	B-cell lymphoma
158	Ganitumab[82]		mab	human	IGF-1 receptor (CD221)	cancer
161	Gemtuzumab ozogamicin	Mylotarg	mab	humanized	CD33	acute myelogenous leukemia
163	Girentuximab[43]	Rencarex	mab	chimeric	carbonic anhydrase 9 (CA-IX)	clear cell renal cell carcinoma[84]
164	Glembatumumab vedotin[85][86]		mab	human	GPNMB	melanoma, breast cancer
170	Icrucumab[88]		mab	human	VEGFR-1	cancer etc.
173	IMAB362		mab	human	CLDN18.2	gastrointestinal adenocarcinomas and pancreatic tumor
174	Imalumab[23]		mab	human	MIF	cancer
176	Imgatuzumab[51]		mab	humanized	EGFR	cancer
178	Indatuximab ravtansine[30]		mab	chimeric	SDC1	cancer
179	Indusatumab vedotin[20]		mab	human	GUCY2C	cancer
180	Inebilizumab[8]		mab	humanized	CD19	cancer, systemic sclerosis, multiple sclerosis
182	Intetumumab[89][90][91]		mab	human	CD51	solid tumors (prostate cancer, melanoma)
185	Ipilimumab[45]	Yervoy	mab	human	CD152	melanoma
186	Iratumumab[45]		mab	human	CD30 (TNFRSF8)	Hodgkin's lymphoma
187	Isatuximab[92]		mab	chimeric	CD38	cancer
191	Labetuzumab[55]	CEA-Cide	mab	humanized	CEA	colorectal cancer
201	Lexatumumab[2]		mab	human	TRAIL-R2	cancer
203	Lifastuzumab vedotin[95]		mab	humanized	phosphate-sodium co-transporter	cancer
206	Lintuzumab		mab	humanized	CD33	cancer
207	Lirilumab[51]		mab	human	KIR2D	solid and hematological cancers
210	Lorvotuzumab mertansine		mab	humanized	CD56	cancer
211	Lucatumumab[10]		mab	human	CD40	multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
213	Lumiliximab[6]		mab	chimeric	CD23 (IgE receptor)	chronic lymphocytic leukemia
214	Lumretuzumab[23]		mab	humanized	ERBB3 (HER3)	cancer
215	MABp1	Xilonix	mab	human	IL1A	colorectal cancer
216	Mapatumumab[22]		mab	human	TRAIL-R1	cancer
217	Margetuximab[98]		mab	humanized	ch4D5	cancer
220	Matuzumab[19]		mab	humanized	EGFR	colorectal, lung and stomach cancer
223	Milatuzumab[10]		mab	humanized	CD74	multiple myeloma and other hematological malignancies
225	Mirvetuximab soravtansine[100]		mab	chimeric	folate receptor alpha	cancer
227	Mogamulizumab[101]		mab	humanized	CCR4	cancer
237	Narnatumab[104]		mab	human	RON	cancer
242	Necitumumab[105]		mab	human	EGFR	non-small cell lung carcinoma
245	Nesvacumab[107]		mab	human	angiopoietin 2	cancer
246	Nimotuzumab[45][108]	Theracim, Theraloc	mab	humanized	EGFR	squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
247	Nivolumab[109]	Opdivo	mab	human	PD-1	cancer
250	Obinutuzumab	Gazyva	mab	humanized	CD20	Chronic lymphatic leukemia
251	Ocaratuzumab[111]		mab	humanized	CD20	cancer
254	Ofatumumab[22]	Arzerra	mab	human	CD20	chronic lymphocytic leukemia etc.
255	Olaratumab		mab	human	PDGF-R α	cancer
258	Onartuzumab[112]		mab	humanized	human scatter factor receptor kinase	cancer
259	Ontuxizumab[113]		mab	chimeric/humanized	TEM1	cancer
261	Oportuzumab monatox[105]		scFv	humanized	EpCAM	cancer
265	Otlertuzumab[115]		mab	humanized	CD37	cancer
271	Pamrevlumab[8]		mab	human	CTGF	idiopathic pulmonary fibrosis (IPF), pancreatic cancer
272	Panitumumab[68]	Vectibix	mab	human	EGFR	colorectal cancer
273	Pankomab		mab	humanized	tumor specific glycosylation of MUC1	ovarian cancer
275	Parsatuzumab[51]		mab	human	EGFL7	cancer
277	Pasotuxizumab[23]		mab	chimeric/humanized	folate hydrolase	cancer
279	Patritumab[37]		mab	human	ERBB3 (HER3)	cancer
280	Pembrolizumab[119]		mab	humanized	PDCD1	melanoma and other cancers
283	Pertuzumab	Omnitarg	mab	humanized	HER2/neu	cancer
285	Pidilizumab[120]		mab	humanized	PD-1	cancer and infectious diseases
286	Pinatuzumab vedotin[26]		mab	humanized	CD22	cancer
291	Polatuzumab vedotin[26][122]		mab	humanized	CD79B	cancer
296	Pritumumab		mab	human	vimentin	brain cancer
300	Radretumab[21]		mab	human	fibronectin extra domain-B	cancer
303	Ramucirumab	Cyramza	mab	human	VEGFR2	solid tumors
309	Rilotumumab[126]		mab	human	HGF	solid tumors
312	Rituximab	MabThera, Rituxan	mab	chimeric	CD20	lymphomas, leukemias, some autoimmune disorders
314	Robatumumab		mab	human	IGF-1 receptor (CD221)	cancer
321	Sacituzumab govitecan[130]		mab	humanized	tumor-associated calcium signal transducer 2	cancer
322	Samalizumab[131]		mab	humanized	CD200	cancer
327	Seribantumab[26]		mab	human	ERBB3 (HER3)	cancer
330	Sibrotuzumab		mab	humanized	FAP	cancer
331	SGN-CD19A		mab	humanized	CD19	acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
332	SGN-CD33A		mab	humanized	CD33	Acute myeloid leukemia
334	Siltuximab		mab	chimeric	IL-6	cancer
338	Sofituzumab vedotin[136]		mab	humanized	CA-125	ovarian cancer
346	Tabalumab[138]		mab	human	BAFF	B-cell cancers
347	Tacatuzumab tetraxetan	AFP-Cide	mab	humanized	alpha-fetoprotein	cancer
353	Tarextumab[139]		mab	human	Notch receptor	cancer
359	Teprotumumab[140]		mab	human	IGF-1 receptor (CD221)	hematologic tumors
361	Tetulomab		mab	humanized	CD37	cancer[141]
364	Ticilimumab (= tremelimumab)		mab	human	CTLA-4	cancer
366	Tigatuzumab[10]		mab	humanized	TRAIL-R2	cancer
369	TNX-650		?	humanized	IL-13	Hodgkin's lymphoma
374	Tovetumab[143]		mab	human	CD140a	cancer
376	Trastuzumab	Herceptin	mab	humanized	HER2/neu	breast cancer
377	Trastuzumab emtansine	Kadcyla	mab	humanized	HER2/neu	breast cancer
378	TRBS07[145]	Ektomab	3funct	?	GD2 ganglioside	melanoma
380	Tremelimumab		mab	human	CTLA-4	cancer
382	Tucotuzumab celmoleukin[45][108]		mab	humanized	EpCAM	cancer
384	Ublituximab[21]		mab	chimeric	MS4A1	cancer
385	Ulocuplumab[147]		mab	human	CXCR4 (CD184)	hematologic malignancies
386	Urelumab[148]		mab	human	4-1BB (CD137)	cancer etc.
389	Utomilumab[32]		mab	human	4-1BB (CD137)	cancer
391	Vandortuzumab vedotin[20]		mab	humanized	STEAP1	cancer
392	Vantictumab[149]		mab	human	Frizzled receptor	cancer
393	Vanucizumab[23]		mab	humanized	angiopoietin 2	cancer
395	Varlilumab[150]		mab	human	CD27	solid tumors and hematologic malignancies
398	Veltuzumab[10]		mab	humanized	CD20	non-Hodgkin's lymphoma
400	Vesencumab[21]		mab	human	NRP1	solid malignancies
403	Volociximab[22]		mab	chimeric	integrin α5β1	solid tumors
404	Vorsetuzumab mafodotin[151]		mab	humanized	CD70	cancer
405	Votumumab	HumaSPECT	mab	human	tumor antigen CTAA16.88	colorectal tumors
407	Zalutumumab[22]	HuMax-EGFr	mab	human	EGFR	squamous cell carcinoma of the head and neck
409	Zatuximab[51]		mab	chimeric	HER1	cancer
